Will FLUOROPHARMA MEDICAL (OTCMKTS:FPMI) Run Out of Steam Soon? Short Interest Is Down

February 12, 2018 - By Kurt Siggers

The stock of FLUOROPHARMA MEDICAL (OTCMKTS:FPMI) registered a decrease of 97.37% in short interest. FPMI’s total short interest was 100 shares in February as published by FINRA. Its down 97.37% from 3,800 shares, reported previously.

It closed at $0.15 lastly. It is down 0.00% since February 12, 2017 and is . It has underperformed by 16.70% the S&P500.

FluoroPharma Medical, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of molecular imaging pharmaceuticals with initial applications in the area of cardiology in the United States. The company has market cap of $5.17 million. The Company’s product candidates include BFPET, an imaging agent that has completed a Phase I clinical trial in stress-testing for patients with presumptive or proven coronary artery disease ; and CardioPET, a molecular imaging agent, which is in Phase IIa clinical trial to assess myocardial blood flow and metabolism in patients with CAD. It currently has negative earnings. The firm has license agreements with Massachusetts General Hospital and Sinotau USA; and clinical research agreements with Pharmaceutical Product Development, LLC, as well as Cardiovascular Imaging Technologies.

More important recent FluoroPharma Medical, Inc. (OTCMKTS:FPMI) news were published by: Forbes.com which released: “PET Imaging Market Poised To Grow With New Compounds” on January 10, 2014, also Marketwired.com published article titled: “FluoroPharma Announces a Letter of Intent to Acquire Ground Fluor Pharmaceuticals”, Globenewswire.com published: “FluoroPharma Announces Closing of Stock Buyback Transaction” on January 10, 2018. More interesting news about FluoroPharma Medical, Inc. (OTCMKTS:FPMI) was released by: Seekingalpha.com and their article: “ARM Holdings’ Biotech Twin: FluoroPharma” with publication date: April 17, 2013.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.